WO2009074350A3 - Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma - Google Patents

Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma Download PDF

Info

Publication number
WO2009074350A3
WO2009074350A3 PCT/EP2008/010824 EP2008010824W WO2009074350A3 WO 2009074350 A3 WO2009074350 A3 WO 2009074350A3 EP 2008010824 W EP2008010824 W EP 2008010824W WO 2009074350 A3 WO2009074350 A3 WO 2009074350A3
Authority
WO
WIPO (PCT)
Prior art keywords
monitoring
treatment
fib
biomarkers
hepatocellular carcinoma
Prior art date
Application number
PCT/EP2008/010824
Other languages
French (fr)
Other versions
WO2009074350A2 (en
Inventor
Jürgen BORLAK
Guiseppe Gazzana
Original Assignee
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. filed Critical Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Priority to US12/744,977 priority Critical patent/US20110136137A1/en
Priority to EP08859212A priority patent/EP2220504A2/en
Publication of WO2009074350A2 publication Critical patent/WO2009074350A2/en
Publication of WO2009074350A3 publication Critical patent/WO2009074350A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention is directed to biomarkers for determining the EGFR kinase activity in a subject, and the use thereof for predicting and monitoring therapeutic intervention in cancer patients. Areas of application are the life sciences: biology, biochemistry, biotechnology, medicine and medical technology. The biomarkers are selected from a first group consisting of Amy 1, Apo Al, Carbx, Casp, AFP, ApoM, SAP, Fib-a, Fib-b, Fib-g, ApoE, A2MG, A2MG isoform, Serpin, Clusterin, MHC-fB, SAP isoform, or from a second group consisting of Gpx3, properidin, MUP1, HMW-K, Lifr-p, Orm 1, MBL-A, MBP-C, wherein the biomarkers are regulated by EGF overexpression in a subject.
PCT/EP2008/010824 2007-12-13 2008-12-11 Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma WO2009074350A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/744,977 US20110136137A1 (en) 2007-12-13 2008-12-11 Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma
EP08859212A EP2220504A2 (en) 2007-12-13 2008-12-11 Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07076092A EP2071336A1 (en) 2007-12-13 2007-12-13 Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma
EP07076092.1 2007-12-13

Publications (2)

Publication Number Publication Date
WO2009074350A2 WO2009074350A2 (en) 2009-06-18
WO2009074350A3 true WO2009074350A3 (en) 2009-09-03

Family

ID=39863009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/010824 WO2009074350A2 (en) 2007-12-13 2008-12-11 Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma

Country Status (3)

Country Link
US (1) US20110136137A1 (en)
EP (2) EP2071336A1 (en)
WO (1) WO2009074350A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102928581A (en) * 2012-11-12 2013-02-13 中国农业科学院北京畜牧兽医研究所 External measurement method for transgenic plant material digestibility

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010049103A1 (en) * 2008-10-31 2010-05-06 Eth Zurich Soluble truncated apom proteins and medical uses thereof
DK2504363T3 (en) 2009-11-24 2019-07-29 Alethia Biotherapeutics Inc ANTI-CLUSTERIN ANTIBODIES AND ANTI-BINDING FRAGMENTS AND THEIR USE TO REDUCE TUMOR VOLUME
JP5873804B2 (en) * 2009-12-22 2016-03-01 エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． Epidermal growth factor receptor (EGFR) protein SRM / MRM assay
US20130203650A1 (en) * 2010-08-31 2013-08-08 Yissum Research Development Company Of The Hebrew Uviversity Of Jerusalem Polypeptides derived from alpha-1 antitrypsin and methods of use thereof
US9518107B2 (en) 2010-08-31 2016-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof
MX2014010164A (en) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer.
WO2014013051A1 (en) * 2012-07-19 2014-01-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of predicting or diagnosing an hepatic encephalopathy in patients with cirrhosis treated with transjugular intra-hepatic porto-systemic shunt (tips)
GB201322574D0 (en) * 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides
GB201322800D0 (en) 2013-12-20 2014-02-05 Univ Dublin Prostate cancer biomarkers
US10035848B2 (en) * 2014-01-08 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody targeting cell surface deposited complement protein C3d and use thereof
GB201602210D0 (en) * 2016-02-08 2016-03-23 Ucl Business Plc Detection of cancer
EP3251687A1 (en) * 2016-06-01 2017-12-06 Centrum Innowacji Edoradca Sp. z o.o. Spolka Komandytowa Bioactive peptides for blood glucose control
US11028138B2 (en) 2016-07-02 2021-06-08 Virongy L.L.C. Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens
CN107064522B (en) * 2017-04-01 2018-11-20 北京博辉瑞进生物科技有限公司 The quantitative detecting method of fibronectin and application in a kind of acellular matrix material
US20220296707A1 (en) * 2019-06-04 2022-09-22 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
CN111423491B (en) * 2020-04-20 2022-09-06 山东省科学院生物研究所 Active decapeptide and application thereof in preparation of auditory hair cell protection product
CN113917149B (en) * 2021-09-30 2024-05-24 江苏扬新生物医药有限公司 Application of gelsolin detector in preparation of uterine cancer assessment detection reagent
CN115144590B (en) * 2022-08-01 2023-04-07 广州达安临床检验中心有限公司 Application of ARC as liver cancer diagnosis marker

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053534A1 (en) * 2000-05-10 2001-12-20 James Mullin Early diagnosis of cancerous and precancerous conditions by leakage of signature peptides and carbohydrates into the bloodstream
US20060211060A1 (en) * 2005-03-16 2006-09-21 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053534A1 (en) * 2000-05-10 2001-12-20 James Mullin Early diagnosis of cancerous and precancerous conditions by leakage of signature peptides and carbohydrates into the bloodstream
US20060211060A1 (en) * 2005-03-16 2006-09-21 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BORLAK JÜRGEN ET AL: "Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours.", ONCOGENE 10 MAR 2005, vol. 24, no. 11, 10 March 2005 (2005-03-10), pages 1809 - 1819, XP002501080, ISSN: 0950-9232 *
CHATTERJI BIJON ET AL: "Serum proteomics of lung adenocarcinomas induced by targeted overexpression of c-raf in alveolar epithelium identifies candidate biomarkers.", PROTEOMICS NOV 2007, vol. 7, no. 21, November 2007 (2007-11-01), pages 3980 - 3991, XP002501081, ISSN: 1615-9853 *
GAZZANA GIUSEPPE ET AL: "Mapping of the serum proteome of hepatocellular carcinoma induced by targeted overexpression of epidermal growth factor to liver cells of transgenic mice.", JOURNAL OF PROTEOME RESEARCH MAR 2008, vol. 7, no. 3, March 2008 (2008-03-01), pages 928 - 937, XP002501082, ISSN: 1535-3893 *
MIFFLIN T E ET AL: "Rapid quantitative, specific measurement of pancreatic amylase in serum with use of a monoclonal antibody.", CLINICAL CHEMISTRY AUG 1985, vol. 31, no. 8, August 1985 (1985-08-01), pages 1283 - 1286, XP002501079, ISSN: 0009-9147 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102928581A (en) * 2012-11-12 2013-02-13 中国农业科学院北京畜牧兽医研究所 External measurement method for transgenic plant material digestibility
CN102928581B (en) * 2012-11-12 2014-08-06 孙哲 External measurement method for transgenic plant material digestibility

Also Published As

Publication number Publication date
WO2009074350A2 (en) 2009-06-18
EP2220504A2 (en) 2010-08-25
US20110136137A1 (en) 2011-06-09
EP2071336A1 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
WO2009074350A3 (en) Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma
WO2003029421A3 (en) Regulated breast cancer genes
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
WO2011035001A3 (en) Novel heparin entities and methods of use
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
WO2006131599A3 (en) Method of profiling a cell population
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
WO2006055525A3 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
ATE511645T1 (en) TEST METHOD FOR DETECTING ANTIBODIES AGAINST LYSOSOME ENZYMES
WO2009019367A3 (en) Apolipoprotein ai assay method for the in vitro diagnosis of colorectal cancer
WO2010093872A3 (en) Molecular-based method of cancer diagnosis and prognosis
CY1113525T1 (en) KATHEHINI TARGETING THERAPY S
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2003063773A3 (en) Differentially-regulated prostate cancer genes
WO2003040331A3 (en) Prostate cancer genes
WO2010010000A3 (en) Screening method, diagnostic method and small nucleic acid for the treatment of cns disorders
WO2008137733A3 (en) Micellar structures, methods of making micellar structures, methods of imaging, and methods of delivering agents
ATE545867T1 (en) I-PLASTIN TEST METHOD FOR IN VITRO DIAGNOSIS OF COLORECTAL CARCINOMA
WO2002081638A3 (en) Prostate cancer expression profiles
WO2009019366A3 (en) Aminoacylase 1 assay method for the in vitro diagnosis of colorectal cancer
WO2005089123A3 (en) Therapeutic anti-cancer dna
EA200701894A1 (en) LEVEL OF TRANSCRIPTION OF THE TIMP3 GENE AS A DIAGNOSTIC MARKER FOR NON-SMALL-CELL LUNG CANCER
WO2005017102A3 (en) Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2010028820A3 (en) Peripheral zone tumor cells, methods for their preparation and use
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08859212

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008859212

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12744977

Country of ref document: US